Clinical Trials on Scarring Alopecia in Ireland

Total 6 results

Concert Pharmaceuticals

Completed

A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Alopecia Areata

Spain, United States, Poland, Canada, France, Germany, Hungary
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)

Alopecia Areata

United States, Canada, Poland, France, Spain
Eli Lilly and Company
Incyte Corporation

Active, not recruiting

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

Alopecia Areata

China, United States, Puerto Rico, Korea, Republic of, Taiwan, Australia, Israel, Japan, Argentina, Brazil
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
AstraZeneca
Duke Clinical Research Institute

Completed

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS)

Cost Sharing, Acute Coronary Syndrome

United States, Puerto Rico

3

Subscribe